The genes regulating circulating levels of soluble gp130 (sgp130), the antagonist of the inflammatory response in atherosclerosis driven by interleukin 6, are largely unknown. Aims of the present study were to identify genetic loci associated with circulating sgp130 and to explore the potential association between variants associated with sgp130 and markers of subclinical atherosclerosis. The study is based on IMPROVE (n = 3703), a cardiovascular multicentre study designed to investigate the determinants of carotid intima media thickness, a measure of subclinical atherosclerosis.
Bonomi A, Veglia F, Baldassarre D, Strawbridge RJ, Golabkesh Z, Sennblad B, Leander K, Smit AJ, Giral P, Humphries SE, Tremoli E, Hamsten A, de Faire U, Gigante B; on behalf of the IMPROVE study group. Analysis of the genetic variants associated with circulating levels of sgp130. Results from the IMPROVE study. Genes Immun 2020 Jan 14. doi: 10.1038/s41435-019-0090-z.